Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
GSK and Flagship to jointly fund up to $150 million upfront
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Subscribe To Our Newsletter & Stay Updated
